Treating, Not Punishing: The Case for Health-Based Addiction Policy

Introduction

Addiction is a chronic brain disorder characterized by compulsive substance use or behavior despite harmful consequences, driven by neurobiological changes in the brain's reward, stress, and self-control circuits. The American Society of Addiction Medicine formally adopted this disease-model definition in 2011, marking a significant shift away from moral-failure frameworks that had dominated public and legal discourse for most of the twentieth century. That definitional shift carries profound policy implications: if addiction is a medical condition rooted in altered brain chemistry, then the appropriate societal response is treatment and public health intervention — not prosecution, incarceration, and punishment. The United States, along with much of the world, has spent decades enforcing a punitive approach to drug use that demonstrably fails the people it claims to address. This essay argues that addiction policy must be restructured around health-centered models because the neuroscientific evidence for addiction as a brain disorder is robust, criminalization consistently produces worse health and social outcomes than treatment alternatives, and jurisdictions that have adopted medical frameworks — most prominently Portugal — demonstrate that decriminalization paired with robust treatment infrastructure reduces drug-related harm without increasing use.

The scientific consensus on the neurobiological basis of addiction has solidified over several decades of research. Substance use disorders involve measurable, long-lasting changes to the prefrontal cortex, the nucleus accumbens, and the amygdala — regions governing decision-making, reward anticipation, and stress response. These changes are not matters of moral weakness or insufficient willpower; they are structural and functional alterations that impair a person's capacity to choose freely in the domains most affected by their addiction. The National Institute on Drug Abuse has consistently characterized addiction as a brain disease that disrupts motivation and memory systems, producing the compulsive drug-seeking behavior that defines severe substance use disorder.

Addiction as a Brain Disorder

Neuroscientist Nora Volkow, who served as Director of the National Institute on Drug Abuse for two decades, has argued extensively that brain imaging research — particularly studies using positron emission tomography — reveals consistent deficits in dopaminergic function among people with severe substance use disorders. These deficits correlate with diminished impulse control and heightened reactivity to drug-associated cues, explaining both the compulsivity of addiction and the high rates of relapse during recovery. The implication is critical: because relapse is a predictable feature of a chronic brain condition, it should be treated the way relapse in diabetes or hypertension is treated — with adjusted care, not with criminal sanction.

Philosopher and addiction theorist Gene Heyman, who has offered a more behavioral account in his work Addiction: A Disorder of Choice, argues that choice plays a meaningful role in addiction, a view that sometimes gets recruited into arguments for punitive policy. But even Heyman's account does not support criminalization; he explicitly notes that most people with addiction disorders recover when their circumstances and incentives change significantly — which points toward social support and treatment, not incarceration. The disease model and more behavioral accounts converge on the same policy conclusion: people experiencing addiction need therapeutic environments, not carceral ones.

The War on Drugs, formally declared by President Richard Nixon in 1971, represents the most sustained experiment in punitive addiction policy in modern history. Over fifty years, the United States has spent more than one trillion dollars on drug enforcement, incarcerated millions of people for drug-related offenses, and produced a society in which drug overdose deaths have risen steadily — reaching more than 100,000 in a single twelve-month period in 2021, according to data from the Centers for Disease Control and Prevention. By any health outcome measure, the punitive approach has failed.

The Failure of Criminalization

Sociologist Michelle Alexander, in her landmark work The New Jim Crow: Mass Incarceration in the Age of Colorblindness (2010), documents how drug enforcement policies have operated with stark racial disparity. Despite broadly similar rates of drug use across racial groups, Black Americans are arrested, prosecuted, and imprisoned for drug offenses at rates far exceeding their white counterparts. Alexander argues that this disparity is not accidental but structural, embedded in the discretionary enforcement choices at every stage of the criminal justice process. This racial dimension of criminalization is not merely an equity concern separate from the health debate; it is evidence that punitive policy is not applied according to any coherent public health logic. If the goal were genuinely to reduce harm, enforcement would follow evidence of harm rather than patterns of racial geography and policing legacy.

Public health researcher Carl Hart, in his book Drug Use for Grown-Ups: Chasing Liberty in the Land of Fear (2021), challenges the premise that drug use is inherently pathological, arguing that the majority of people who use controlled substances do not develop addiction and function productively. Hart's work — which draws on both his scientific research and autobiographical disclosure — illustrates the cost of treating all drug use as a criminal problem: it drives use underground, discourages people from seeking treatment, and stigmatizes an enormous population who would benefit from honest, science-based information rather than legal threat. Criminalization does not stop drug use; it makes drug use more dangerous.

The Portuguese Model and Evidence for Health-Centered Policy

The most compelling real-world evidence for health-centered addiction policy comes from Portugal's drug decriminalization program, implemented in 2001. Facing a severe heroin epidemic in the 1990s — with one of the highest rates of HIV infection linked to intravenous drug use in Europe — Portugal decriminalized the personal possession of all drugs and redirected resources toward treatment, harm reduction, and social reintegration. The results, studied extensively by researchers including Glenn Greenwald in a 2009 Cato Institute report, were striking: HIV infection rates among people who inject drugs dropped dramatically, drug-related deaths fell, and drug use rates did not increase relative to European neighbors who maintained criminalization.

Counterargument: The Case for Maintaining Legal Deterrence

Portugal's model works not through decriminalization alone but through the "Dissuasion Commission" system, which routes people found with personal quantities of drugs to panels composed of social workers, legal experts, and health professionals. These panels assess each person's situation and recommend treatment, community service, or administrative fines — all framed within a public health logic rather than a punitive one. The critical insight is that removing the threat of incarceration reduces barriers to seeking help. When a person struggling with addiction knows that asking for treatment will not result in a criminal record, they are far more likely to seek it.

Similar evidence emerges from harm reduction programs in other jurisdictions. Supervised injection facilities — established in Switzerland in the 1980s and later in Canada and several European nations — have been studied extensively and consistently shown to reduce overdose deaths, decrease public injecting, and connect participants to treatment services without increasing drug use in surrounding communities. The Canadian Supreme Court's 2011 decision in Canada (Attorney General) v. PHS Community Services Society upheld the legality of Vancouver's Insite supervised injection facility precisely on the grounds that preventing its closure would cause preventable death — a judicial recognition that health considerations must take precedence over punitive instinct when lives are at stake.

The strongest opposition to health-centered addiction policy does not come from bad-faith actors who simply want to punish the poor; it comes from a coherent position that legal deterrence serves genuine protective functions, and that fully decriminalizing drug possession sends a social signal that undermines prevention. A thoughtful proponent of this view would argue as follows: drugs cause real harm — not only to users, but to families, communities, and public systems. Laws encode social norms. When a society declares something illegal, it communicates that the behavior is unacceptable, and this normative signal deters some people, particularly adolescents and young adults, from initiation. If decriminalization increases the perceived permissibility of drug use, it may increase experimentation, leading more people into the disorder that health advocates rightly want to prevent. Furthermore, the proponent might argue, some degree of legal pressure is actually therapeutic — drug courts and diversion programs use the coercive leverage of the legal system to push resistant individuals into treatment they would not otherwise accept. On this view, removing criminal consequences entirely may remove one of the few effective motivational levers available for the most severely affected users.

This argument deserves a serious response because it contains real partial truths. Drug courts have shown some evidence of effectiveness, and coercive pathways into treatment do succeed for some individuals. The deterrence claim also cannot be dismissed entirely; legal status does influence behavior at the margins for some populations.

However, the argument fails on several decisive grounds. First, the deterrence effect of drug criminalization is empirically weak for people already experiencing addiction, precisely because severe substance use disorder impairs the rational cost-benefit calculations on which deterrence theory depends. A person in the grip of compulsive drug-seeking behavior — whose prefrontal cortex function is measurably compromised — is not effectively deterred by legal consequences in the way a rational actor would be. Second, Portugal's experience directly refutes the claim that decriminalization increases use: drug use rates did not rise after 2001, and the country achieved significant harm reduction gains. Third, the most effective drug courts are those that maximize treatment engagement and minimize incarceration — they succeed, where they do, because of the treatment component, not the criminal threat. Expanding treatment access without the criminal infrastructure would achieve the same therapeutic benefits without the devastating collateral consequences: employment barriers, housing exclusions, child custody losses, and civic disenfranchisement that criminal records impose on people whose primary problem is a medical one. The deterrence model ultimately asks sick people to be deterred out of their illness — a standard applied to no other chronic disease.

Conclusion

Addiction is a chronic brain disorder — not a character defect, not a moral failure, and not a problem that incarceration has the power to cure. Fifty years of the War on Drugs have produced overcrowded prisons, decimated communities, racially stratified criminal records, and a mounting death toll that accelerated rather than abated under the weight of punitive enforcement. The neuroscience is clear, the comparative policy evidence is compelling, and the ethical argument is decisive: people who are sick deserve treatment, not punishment.

The counterargument from deterrence is not without merit in its narrowest applications — coercive pathways into treatment have value, and legal frameworks will always shape social norms to some degree. But deterrence theory cannot be stretched to justify a system that criminalizes a medical condition, applies enforcement with racial inequity, and drives vulnerable people away from the help that could save their lives. Portugal demonstrated in 2001 that a different approach is possible. Canada's harm reduction jurisprudence confirms it. The science of addiction biology demands it.

What is at stake in getting this question wrong is not abstract. Every year that addiction policy remains anchored in punishment rather than treatment, tens of thousands of people die of preventable overdoses, hundreds of thousands cycle through jails without receiving care, and the illness deepens in communities already burdened by poverty and disinvestment. Reforming addiction policy toward a health-centered model is one of the clearest cases in contemporary public policy where the evidence and the ethics point in the same direction. The obstacle is not knowledge. It is political will. And the cost of maintaining punitive policy — measured in human lives — grows higher with every year of inaction.